Collagen & Gelatin for Regenerative Medicine Market is segmented By Type (Collagen, Gelatin), By Source (Bovine, Porcine, Marine, Others), By Application (Orthopedic, Wound Care, Cardiovascular, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Collagen & Gelatin for Regenerative Medicine Market Size
The Global Collagen & Gelatin for Regenerative Medicine Market was valued at US$ 605.29 million in 2021 and is estimated to reach US$ 1,184.37 million by 2031, growing at a CAGR of 10.67% during the forecast period (2024-2031).
Gelatin and collagen are proteins mainly found in the skin and bones but are present throughout the human body. After a specific age, the natural collagen generation in the body diminishes. The absence of collagen aggravates and promotes chronic ailments such as osteoporosis, chronic wounds, cardiovascular diseases, bone and joint discomfort, and neurodegenerative disorders.
Collagen & Gelatin for Regenerative Medicine Market Summary
|
Metrics |
Details |
|
Market CAGR |
10.67% |
|
Segments Covered |
By Type, By Source, By Application and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Market Dynamics
The increasing demand for these collagen & gelatin for regenerative medicines is due to the rising incidence of bone-related disorders. The rising number of research and development expenditures and growth in novel product launches are expected to drive market growth.
The increasing number of novel product launches and rising research and development or clinical studies will drive market growth.
The global market for collagen & gelatin for regenerative medicine is primarily driven by the healthcare industry's demand for these innovative products due to increasing illnesses, including osteoporosis and osteoarthritis. Chronic diseases can result in organ and tissue loss which drives the development of collagen and gelatin-based biomaterials for regenerative medicine. Its purpose in regenerative medicine has been growing substantially over the past few decades owing to the significant advantage of being biodegradable, biocompatible, low immunogenicity, readily available, and highly versatile, boosting the growth of the collagen and gelatin market for regenerative medicine. The rising number of research and development studies on collagen and gelatin’s regenerative properties are driving the market’s growth.
Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these collagen & gelatin for regenerative medicine. For instance, in Mar 2022, Integra LifeSciences Corporation, medical technology company, launched its NeuraGen 3D Nerve guide Matrix. It’s a nerve repair resorbable implant as it repairs discontinuities of the peripheral nerve that provides an optimized environment for may give high complete functional recovery.
The high costs associated with collagen & gelatin regenerative medicine will hamper the market’s growth.
However, high rates of collagen & gelatin regenerative medicine are the major factor restraining the growth. The availability of alternative biomaterials in the market may hinder the collagen & gelatin market growth.
COVID-19 Impact Analysis
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The collagen & gelatin regenerative medicine market has experienced huge losses due to COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in Oct 2021, Symstese and L’Oreal signed a long-term R&D agreement in the biomaterial field in which they will study novel scientific perspectives of biomaterial developed for human tissues for regeneration.
Segmentation Analysis
The orthopedic segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The Orthopedic segment is the highest market holder in the global collagen & gelatin for regenerative medicine market. In orthopedics, collagen fleece is used after open fractures, arthroplasty, amputations or spine surgery as prophylaxis. According to Climatric, a journal of the International Menopause Society report in 2021, Osteoporosis is the leading cause of over 8.9 million fractures yearly. Estimated that around 200 million women are affected with osteoporosis globally.
The rising number of people suffering from bone-related disorders and growing technological advancements or research/clinical trial studies drive the market’s growth. For Instance, in Sep 2021, PB Leiner announced the evidence based on a clinical study conducted to inspect joint pain in middle-aged physically active people who consume SOLUGEL collagen peptide. The study showed a significant reduction in discomfort and pain people were dealing with. This research was done by Florida State University and authorized by PB Leiner.
Geographical Share
North America holds the largest market share of the global collagen & gelatin for regenerative medicine market.
North America dominates the global collagen & gelatin for regenerative medicine market, primarily attributed to the rising prevalence of bone or joint-related ailments such as osteoporosis, osteoarthritis and many more; established healthcare infrastructure and higher investment in R&D activities contribute to North America’s rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the Osteoarthritis Action Alliance, in 2021, more than 32.5 million U.S. people have osteoarthritis, affecting around 25% of the world’s population.
Moreover, the growing number of product launches is responsible for the market’s growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market’s growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Jan 2021, Integra Lifesciences Corporation announced that they completed the acquisition of ACell Inc. ACell is a company of innovative regenerative medicine with products and technology based on a porcine urinary bladder matrix platform.
Market Players and Competitive Landscape
The collagen & gelatin for regenerative medicine market is highly competitive with local and global companies’ presence. Integra Lifesciences Holdings Corporation, Nitta Gelatin, GELITA AG, Collagen Matrix Inc., Blafar Ltd., PB Leiner, Royal DSM, Symatese, Olaregen Therapeutics, Collagen Solutions Plc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in May 2021, Olaregan Therapeutics, a Generex Biotechnology subsidiary, announced its distribution agreement with Nexgen Medical Sdn Bhd Inc. Nexgen will import and market wound care products, Excellagen, in Malaysia.
Integra Lifesciences Holdings Corporation:
Overview:
Integra LifeSciences Corp is a medical technology company that provides high-quality neurosurgical and regenerative tissue technology products, including Bactiseal, CerebroFlo, DuraSeal, Integra, MicroMatrix and many more.
Product Portfolio:
SurgiMend: It is a novel acellular collagen matrix extracted from the neonatal and fetal bovine dermis. It provides advantages for soft tissue reconstruction and repair over other biological or synthetic products.
Key Development: In Jul 2021, Integra LifeSciences Corporation, a company in medical technology, announced receiving a contract for innovative technology from Vizient Inc., a company of healthcare performance improvement for its soft tissue reconstruction product SurgiMend.
The global collagen & gelatin for regenerative medicine market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.
